SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep3 | 5 | Human | HLA-A02_01,HLA-A29_02,HLA-B57_01,HLA-B44_03 | ||
SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep4 | 5 | Human | HLA-A02_01,HLA-A29_02,HLA-B57_01,HLA-B44_03 | ||
SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep5 | 5 | Human | HLA-A02_01,HLA-A29_02,HLA-B57_01,HLA-B44_03 | ||
SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep3 | 5 | Human | HLA-A01_01,HLA-A02_01,HLA-B18_01,HLA-B39_24 | ||
SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep4 | 5 | Human | HLA-A01_01,HLA-A02_01,HLA-B18_01,HLA-B39_24 | ||
SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep5 | 5 | Human | HLA-A01_01,HLA-A02_01,HLA-B18_01,HLA-B39_24 | ||
SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject4_rep6 | 5 | Human | HLA-A01_01,HLA-A02_01,HLA-B18_01,HLA-B39_24 |
SYSMHC00008 | SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep4 | SYSMHC00008_Subject3_rep4_021213_Fx600mM.raw | In vitro | suspension | EBV transformed | class I | 26728094 | native | Mild acid elution | Orbitrap Elite | LTQ | no | DDA | CID | 3-60% | 120 | 1 | |||||||
SYSMHC00008 | SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep4 | SYSMHC00008_Subject3_rep4_021213_Fx50mM.raw | In vitro | suspension | EBV transformed | class I | 26728094 | native | Mild acid elution | Orbitrap Elite | LTQ | no | DDA | CID | 3-60% | 120 | 2 | |||||||
SYSMHC00008 | SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep4 | SYSMHC00008_Subject3_rep4_021213_Fx75mM.raw | In vitro | suspension | EBV transformed | class I | 26728094 | native | Mild acid elution | Orbitrap Elite | LTQ | no | DDA | CID | 3-60% | 120 | 3 | |||||||
SYSMHC00008 | SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep4 | SYSMHC00008_Subject3_rep4_021213_Fx100mM.raw | In vitro | suspension | EBV transformed | class I | 26728094 | native | Mild acid elution | Orbitrap Elite | LTQ | no | DDA | CID | 3-60% | 120 | 4 | |||||||
SYSMHC00008 | SYSMHC00008_laumontc_160105_perreault-thibault_cada_LCL_subject3_rep4 | SYSMHC00008_Subject3_rep4_021213_Fx300mM.raw | In vitro | suspension | EBV transformed | class I | 26728094 | native | Mild acid elution | Orbitrap Elite | LTQ | no | DDA | CID | 3-60% | 120 | 5 |